Buy Rating for Aquestive Therapeutics Driven by Anaphylm’s FDA Approval Prospects and Market Potential
Ram Selvaraju from H.C. Wainwright has reiterated a Buy rating on Aquestive Therapeutics, setting a price target of $10.00. This rating is driven by the anticipated FDA approval of Anaphylm, a non-invasive epinephrine product for severe allergic reactions, expected by January 31, 2026. The product's potential peak sales could exceed $280 million by 2034, supported by strategic preparations for its launch. Piper Sandler also maintains a Buy rating with an $8.00 price target. Selvaraju has a 23.3% average return and a 51.40% success rate on his recommendations.
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Aquestive Therapeutics, with a price target of $10.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Ram Selvaraju has given his Buy rating due to a combination of factors surrounding Aquestive Therapeutics’ Anaphylm product. The anticipation of the FDA’s decision on Anaphylm, expected by January 31, 2026, plays a significant role. Anaphylm is poised to be the first FDA-approved, non-invasive, orally delivered epinephrine product for severe allergic reactions, offering a needle-free alternative that could address patient hesitancy associated with injections. The completion of 11 clinical studies and the FDA’s waiver of the advisory committee further bolster confidence in a favorable approval outcome.
Additionally, Aquestive’s strategic preparations for Anaphylm’s launch, including market access optimization and global expansion efforts, enhance the product’s commercial prospects. The company is expanding its infrastructure and meeting key milestones to ensure a successful launch. The potential for Anaphylm to achieve peak sales exceeding $280 million by 2034, coupled with its convenience advantage over existing treatments, underscores the positive outlook. These factors collectively justify the Buy rating and the 12-month price target of $10.
Selvaraju covers the Healthcare sector, focusing on stocks such as Emergent Biosolutions, Bioxcel Therapeutics, and Vanda. According to TipRanks, Selvaraju has an average return of 23.3% and a 51.40% success rate on recommended stocks.
In another report released on November 7, Piper Sandler also maintained a Buy rating on the stock with a $8.00 price target.
